[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370299-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370299-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","response-rate-to-the-intervention-with-tirbanibulin-1-ointment-for-treating-actinic-keratoses-in-people-living-with-hiv-infection","Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection","","People living with HIV (PLWH) show higher susceptibility than immunocompetent individuals to non-melanoma skin cancers, including actinic keratosis (AK) and related precancerous lesions. In this study, retrospective data were collected for PLWH diagnosed with AK who received tirbanibulin 1% ointment between September 2023 and September 2024. AK severity was quantified using lesion counts and the AKASI score at baseline (T0) and after treatment (T1). Ten patients were treated, with average lesion number decreasing from 8.2 to 1.7 and AKASI from 4.20 to 1.5; only two reported mild inflammatory reactions.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/response-rate-to-the-intervention-with-tirbanibulin-1-ointment-for-treating-actinic-keratoses-in-people-living-with-hiv-infection/370299/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/response-rate-to-the-intervention-with-tirbanibulin-1-ointment-for-treating-actinic-keratoses-in-people-living-with-hiv-infection/370299.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective?","Question",{"text":63,"@type":64},"To evaluate the response rate to tirbanibulin 1% ointment for treating actinic keratoses (AKs) in people living with HIV (PLWH).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were AK severity and treatment response assessed?",{"text":68,"@type":64},"By calculating lesion number and the AKASI score at diagnosis (T0) and after treatment (T1).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key results after treatment?",{"text":72,"@type":64},"Across 10 treated patients, lesions decreased on average from 8.2 to 1.7 and AKASI decreased from 4.20 to 1.5.",{"name":74,"@type":61,"acceptedAnswer":75},"How tolerable was tirbanibulin 1% ointment in this group?",{"text":76,"@type":64},"Only two patients reported a mild inflammatory reaction after applying the ointment.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370299,1790676820,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":116,"preview_page_count":33,"preview_urls":149},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nResponse Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection  \nGiulia Ciccarese 1, *, Francesco Drago 2, Lucia Lospalluti 3, Mauro Grandolfo 3, Sergio Lo Caputo 4, Mario Mastrolonardo 1, Benedetta Tirone 3, Cosimo Castronovi 3, Riccardo Bortone 3, Gerardo Cazzato 5 and Caterina Foti 3  \nAcademic Editor: Laurent Bélec  \nReceived: 30 December 2024  \nRevised: 16 January 2025  \nAccepted: 5 February 2025  \nPublished: 7 February 2025  \nCitation: Ciccarese, G.; Drago, F.; Lospalluti, L.; Grandolfo, M.; Lo Caputo, S.; Mastrolonardo, M.; Tirone, B.; Castronovi, C.; Bortone, R.; Cazzato, G.; et al. Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratosesin People Living with HIV Infection. Diagnostics 2025, 15, 401 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)diagnostics15040401  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Unit of Dermatology, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto, 1, 71122 Foggia, Italy; [mario.mastrolonardo@unifg.it](mario.mastrolonardo@unifg.it)  \n2 Casa di Cura Villa Montallegro, Via Monte Zovetto 27, 16100 Genoa, Italy; [francescodrago007@gmail.com](francescodrago007@gmail.com)  \n3 Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70126 Bari, Italy; [lucia.lospalluti@policlinico.ba.it](lucia.lospalluti@policlinico.ba.it) (L.L.); [grandolfo1@alice.it](grandolfo1@alice.it) (M.G.); [benedetta.ti96@gmail.com](benedetta.ti96@gmail.com) (B.T.); [cosimocastronovi90@gmail.com](cosimocastronovi90@gmail.com) (C.C.); [riccardobort@gmail.com](riccardobort@gmail.com) (R.B.); [caterina.foti@uniba.it](caterina.foti@uniba.it) (C.F.)  \n4 Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia,  \n71122 Foggia, Italy; [sergio.locaputo@unifg.it](sergio.locaputo@unifg.it)  \n5 Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy; [gerardo.cazzato@uniba.it](gerardo.cazzato@uniba.it)  \n* Correspondence: [giulia.ciccarese@unifg.it](giulia.ciccarese@unifg.it); Tel.: +39-0881-732205  \nAbstract: Background/Objectives: People living with HIV (PLWH) are more susceptible than immunocompetent people to non-melanoma skin cancers. These tumors can arise de novo or from precancerous lesions, such as actinic keratosis (AKs) . The management of AKsin PLWH has not been widely discussed in the literature. More specifically, the efficacy of the treatment of AKs in PLWH with modern topical drugs, such as tirbanibulin, is limited. The present work aims to evaluate the response rate to the intervention with tirbanibulin 1% ointment for treating AKs in PLWH. Methods: We retrospectively collected the data of the PLWH who visited the Dermatology Department of the Policlinico Riuniti (Foggia, Italy) between September 2023 and September 2024 . PLWH who received the diagnosis of AKs and underwent treatment with tirbanibulin 1% ointment were studied. To assess the severity of AKs, the number of AKs and the AKs’ area and severity index (AKASI) score were calculated at the time of diagnosis (T0) and after treatment (T1) . Results: Ten PLWH were found to have AKs and received topical therapy with tirbanibulin 1% ointment. On average, at T0, the number of lesions was 8.2 and the AKASI score was 4.20; at T1, the number of AKs was 1.7 and the AKASI score was 1.5 . Only two patients reported a mild inflammatory reaction to applying tirbani","cbCaigZxMAopDqNt","https://ap.wps.com/l/cbCaigZxMAopDqNt","pdf",969322,12,"English","# Abstract\n## Background/Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Definition and clinical features of actinic keratosis\n## Etiology and risk factors (ultraviolet exposure)\n## Epidemiology","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To evaluate the response rate to tirbanibulin 1% ointment for treating actinic keratoses (AKs) in people living with HIV (PLWH).\"},{\"question\":\"How were AK severity and treatment response assessed?\",\"answer\":\"By calculating lesion number and the AKASI score at diagnosis (T0) and after treatment (T1).\"},{\"question\":\"What were the key results after treatment?\",\"answer\":\"Across 10 treated patients, lesions decreased on average from 8.2 to 1.7 and AKASI decreased from 4.20 to 1.5.\"},{\"question\":\"How tolerable was tirbanibulin 1% ointment in this group?\",\"answer\":\"Only two patients reported a mild inflammatory reaction after applying the ointment.\"}]","Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection | PDF",1790187847,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b32e34c27d0928d9e7da9dfc192ba06.webp",983,1390,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02ed1ea449629ea371645a9c3bce61d8.webp",982,1388,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d7c9a4d756be47813d96fe9d29f1c74.webp",981,1387,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de6397589529fd615444811ea44ab7a9.webp",980,1385]